Search Results - Jacob Haaber

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    PB2394: PTPRJ AS A ROBUST DIFFERENTIATING MARKER IN MANTLE CELL LYMPHOMA by Simone Valentin Hansen, Mia Koldby Blum, Marcus Høy Hansen, Oriane Cédile, Jacob Haaber, Niels Abildgaard, Charlotte Guldborg Nyvold

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  2. 2

    Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma by Thomas Rasmussen, Jacob Haaber, Inger Marie Dahl, Lene M. Knudsen, Gitte B. Kerndrup, Marianne Lodahl, Hans E. Johnsen, Michael Kuehl

    Published in Haematologica (2010-10-01)
    Get full text
    Article


  3. 3

    Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long‐term follow‐up of the Nordic Lymphoma Group MCL6 Philemon trial by Elin Forsgren, Rasmus R. K. Jørgensen, Hans Bentzen, Jon Riise, Jacob Haaber, Annika Pasanen, Hanne Kuitunen, Karin F. Wader, Tarec C. El‐Galaly, Martin Hutchings, Ingrid Glimelius, Mats Jerkeman

    Published in HemaSphere (2025-03-01)
    Get full text
    Article


  4. 4

    P074: Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients – A Nationwide Danish Cohort Study by Sára Rossetti, Sidsel Jacobsen Juul, Frank Eriksson, Peder Emil Warming, Charlotte Glinge, Tarec Christoffer El-Galaly, Jacob Haaber Christensen, Peter Kamper, Peter De Nully Brown, Maja Vestmø Maraldo, Jacob Tfelt-Hansen, Martin Hutchings

    Published in HemaSphere (2022-10-01)
    Get full text
    Article


  5. 5

    S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS by Anna Sureda, Lorenzo Falchi, Sirpa Leppa, Joost Vermaat, Harald Holte, Martin Hutchings, Pieternella Lugtenburg, Sven de Vos, Pau Abrisqueta, Marcel Nijland, Reid W. Merryman, Jacob Haaber Christensen, Bjorn Wahlin, Kim Linton, Liwei Wang, Aqeel Abbas, Ali Rana, Syed Quadri, David Belada

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  6. 6

    Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study by Trine Trab, Iman Chanchiri, Ahmed Ludvigsen Al-Mashhadi, Emma Berggren Dall, Stine Rasch, Mette Johansen, Simon Husby, Mikkel Runason Simonsen, Michael Roost Clausen, Thomas Stauffer Larsen, Jacob Haaber Christensen, Robert Schou Pedersen, Mikael Frederiksen, Mats Jerkeman, Christian Bjørn Poulsen, Laura Mors Haunstrup, Peter Brown, Tarec Christoffer El-Galaly, Kirsten Grønbæk

    Published in Blood Neoplasia (2025-08-01)
    Get full text
    Article


  7. 7

    Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3 by Christian Winther Eskelund, Kostas Dimopoulos, Arne Kolstad, Ingrid Glimelius, Riikka Räty, Lise Mette Rahbek Gjerdrum, Kristina Sonnevi, Pär Josefsson, Herman Nilsson-Ehle, Hans H. N. Bentzen, Unn Merete Fagerli, Outi Kuittinen, Jacob Haaber, Carsten Utoft Niemann, Lone Bredo Pedersen, Maria Torp Larsen, Christian Hartmann Geisler, Martin Hutchings, Mats Jerkeman, Kirsten Grønbæk

    Published in HemaSphere (2021-01-01)
    Get full text
    Article


  8. 8

    Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up by Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage

    Published in Blood Cancer Journal (2025-08-01)
    Get full text
    Article


Search Tools: